妊娠中の糖尿病のリスクを高める薬物相互作用の検出の信頼性を調査する

Robiyanto Robiyanto^1,2, Jim W Barrett³, Lovisa Sandberg³

¹Department of PharmacoTherapy, -Epidemiology, and -Economics, Groningen Research Institute of Pharmacy, University of Groningen, Antonius Deusinglaan 1, 9713 AV, Groningen, The Netherlands.

Drug safety

|September 2, 2025

まとめ

副作用報告システムでは,妊娠中に抗うつ剤と他の薬剤間の潜在的な薬物相互作用 (DDI) が検出されましたが,レビューではタイミングの不確実性のためにデータが信頼できないことが判明しました.

科学分野:

薬用警戒について
妊娠中の薬物安全性
薬と薬の相互作用

背景:

副作用報告システムは薬物の安全性信号に不可欠です
妊娠中の薬物相互作用 (DDI) を特定する際の有用性はよく確立されていません.

研究の目的:

妊娠中のDDIの薬理学的信号検出の信頼性を,有害事象報告システムを用いて評価する.
抗精神病薬 (AP) や抗うつ薬 (AD) とCYP450調節薬の相互作用に注目し,妊娠糖尿病 (GDM) を増加させる可能性がある.

主な方法:

妊娠に関連した薬物報告のために,WHOの世界的な有害事象データベースであるVigiBaseを利用した.
潜在的なDDIを特定し,検証するために統計分析 (オメガ不均衡) とケースシリーズレビューを使用しました.
関連するCYP450イソエンザイムに対するWHO医薬品標準化薬剤分類に基づいて選択された相互作用薬.

主要な成果:

いくつかの抗うつ薬 (エシタロプラム,シタロプラム,セルトラリン) とCYP2D6阻害剤の間の潜在的なDDIは,より高いGDM報告率と関連している.
しかし,症例シリーズのレビューでは,薬のタイミングが明確でないため,これらのDDIを証明できませんでした.

結論:

DDIの統計的信号は見つかったが,症例レビューでは,薬剤のタイミングの不確実性が明らかになり,信頼性に影響を与えた.
詳細なデータで医薬品警戒信号の検証の必要性を強調し,正確な医薬品報告を強調する.

さらに関連する動画

07:30

Homogeneous Time-resolved Förster Resonance Energy Transfer-based Assay for Detection of Insulin Secretion

Published on: May 10, 2018

9.4K

07:40

A Data Integration Workflow to Identify Drug Combinations Targeting Synthetic Lethal Interactions

Published on: May 27, 2021

4.3K

関連する概念動画

01:19

Pharmacovigilance

983

Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...

983

01:22

Diabetes Mellitus: Type 2 and Gestational

2.9K

Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...

2.9K

01:21

Factors Affecting Drug Response: Overview

2.4K

When it comes to infants and young children, they are typically administered smaller doses of medication in comparison to adults. This is primarily because their organ functions still need to fully develop, meaning their bodies are not as efficient at metabolizing or eliminating drugs. Additionally, their blood-brain barrier is more permeable than in adults. As a result, high concentrations of drugs can easily penetrate the central nervous system (CNS), potentially leading to neurological...

2.4K

01:20

Pathophysiology of Diabetes

1.2K

Diabetes mellitus is a chronic metabolic disorder characterized by hyperglycemia. The four categories of diabetes are type 1 diabetes, type 2 diabetes, other specific types of diabetes, and gestational diabetes.
Type 1 diabetes is characterized by autoimmune-mediated destruction of pancreatic β cells, with environmental factors potentially triggering this process in genetically susceptible individuals. Despite many not having a family history, certain genes increase susceptibility,...

1.2K

01:26

Oral Hypoglycemic Agents: Biguanides and Glitazones

288

Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...

288

01:23

Dipeptidyl Peptidase 4 Inhibitors

252

Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...

252

関連する実験動画